DEBIOPHARM
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today secured an option to enter an exclusive licensing deal with SunRock Biopharma (www.sunrockbiopharma.com), a Galician company supported by the regional government, Xunta de Galicia, through Xes Galicia. SunRock is devoted to the development of sophisticated, bispecific antibodies against highly invasive tumors with an urgent clinical need in oncology and will benefit from Debiopharm’s Multilink™ technology to produce an enhanced HER3-EGFR bispecific antibody-drug conjugate (ADC). This option agreement prolongs the existing partnership that was initiated in September of this year allowing Debiopharm to further develop HER2/HER3 targeting antibodies.
“At Debiopharm, we are actively scouting for opportunities to apply our proprietary linker technology, Multilink™, in a way that complements the licensed antibodies. MultilinkTM has been engineered to produce ADC with high drug to antibody ratio and excellent stability in circulation, to avoid premature drug release, and to increase treatment specificity and effectiveness,” commented Frederic Levy, Chief Scientific Officer of Debiopharm.
Over the past five years, ADCs have gained enormous momentum and become standard-of-care for the treatment of many cancers. The success of this therapeutic class is mainly linked to the possibility of chemically conjugating cytotoxic payloads onto antibodies, thereby combining the targeted specificity of antibodies with the lethality of cytotoxic payloads while minimizing damage to healthy tissue.
"We are thrilled to enhance our partnership with Debiopharm. This collaboration enables us to merge our innovative expertise in bispecific antibodies with Debiopharm's cutting-edge Multilink™ technology. Together, we're paving new paths to address highly aggressive cancers with critical clinical needs. It's a significant step in our quest to deliver more effective, targeted therapies to patients,” commented Laureano Simón, CEO of SunRock Biopharma.
About Multilink™
Multilink™ is a new cleavable linker platform suited for multidrug attachment and compatible with any conjugation technology to produce ADCs with high DAR (drug-to-antibody ratio). This unique and innovative technology allows the loading of multiple payloads on an antibody for an enhanced therapeutic effect. This highly efficient and well-tolerated linker platform is available for use by other specialty biotech or pharmaceutical companies to generate proprietary, clinical-stage ADCs.
About SunRock Biopharma
SunRock Biopharma is a biotech company devoted to the development of therapeutic antibodies against highly invasive tumors with an urgent clinical need. SunRock has developed a unique portfolio of first-in-class and best-in-class therapeutic antibodies and bispecific antibodies against novel targets, such as CCR9 and well-known targets such as HER3.
About Debiopharm
Debiopharm develops innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and international patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialization partners to maximize patient access globally.
Visit us www.debiopharm.com
Follow us on Twitter @DebiopharmNews at http://twitter.com/DebiopharmNews
Follow us on LinkedIn at https://www.linkedin.com/company/debiopharminternational/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240108143318/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S.23.7.2025 22:51:00 CEST | Press release
ANZUPGO® (delgocitinib) cream now becomes the first and only FDA-approved treatment specifically approved for the treatment of adults living with moderate-to-severe chronic hand eczema (CHE) in the U.S.1 CHE affects approximately one in ten adults worldwide, yet previously, there has been no specific treatment FDA-approved for those living with the disease.2,3 The approval represents an important milestone for LEO Pharma’s expanding presence in the U.S. as it broadens its portfolio of dermatology treatments to address unmet needs. LEO Pharma, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream (20 mg/g) for the topical treatment of moderate-to-severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable.1 ANZUPGO is an innovative steroid-free, topical pan-Janus kinase (JAK) inhibitor for adults with CHE.1 ANZUPGO inh
Laserfiche Named a Leader in Nucleus Research Content Services and Collaboration Value Matrix 202523.7.2025 20:00:00 CEST | Press release
Laserfiche is a Leader for the 10th consecutive year, ranks highest in usability. Laserfiche — the leading SaaS provider of intelligent content management and business process automation — is a Leader in the Nucleus Research Technology Value Matrix for Content Services and Collaboration for the 10th year in a row. Among the vendors evaluated, Laserfiche ranks highest overall in usability. Download a copy of the report here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250723109668/en/ Laserfiche is a Leader for the 10th consecutive year. “As a leader in this year’s Value Matrix, Laserfiche was rated highest in usability for its AI productivity tools, new administration hub, process automation and integration capabilities,” said Evelyn McMullen, research manager at Nucleus Research and author of the report. CSC as a Strategic Advantage: AI-powered Information Management Recently released Laserfiche AI-powered features are a
Multiply Group Completes Acquisition of Tendam, Doubling Operational EBITDA and Expanding Global Footprint23.7.2025 19:53:00 CEST | Press release
Tendam is Spain's second-largest apparel group by market share and one of Europe’s leading omnichannel apparel groups. Tendam’s 12 well-established owned fashion brands offer diversity and international exposure, further deepening the Group’s presence in consumer-focused industries. The transaction, valued at AED 5.6 billion (€ 1.3 billion) enterprise value, positions Multiply Group as a key player in the global Retail & Apparel landscape. Multiply Group (ADX: MULTIPLY), the Abu Dhabi-based investment holding company that invests in and operates businesses globally, today completed its first major investment in Europe with the acquisition of a majority stake in Tendam, Spain’s second-largest apparel group by market share1. The deal doubles Multiply’s operational EBITDA post-consolidation and expands its model to acquire standout businesses, unlock potential through capital and tech, and deliver sustained market leadership. This press release features multimedia. View the full release h
General Aviation Community Unites to Support the 2026 Special Olympics Airlift23.7.2025 17:11:00 CEST | Press release
During the industry’s iconic Experimental Aircraft Association (EAA) AirVenture event in Oshkosh, Wisconsin, leading general aviation organizations — including EAA and General Aviation Manufacturers Association (GAMA) — announced their collective support and endorsement of the 2026 Special Olympics Airlift event. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250723984082/en/ Ron Draper, president and CEO, Textron Aviation and Jack J. Pelton, chairman and CEO, Experimental Aircraft Association celebrate the general aviation community uniting to support the 2026 Special Olympics Airlift during the industry’s iconic Experimental Aircraft Association (EAA) AirVenture event in Oshkosh, Wisconsin. (Photo: Textron Aviation) The Special Olympics Airlift, organized by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, mobilizes hundreds of volunteer Cessna, Beechcraft and Hawker pilots and aircraft to create the world’s larg
The University of Melbourne Selects Rimini Street to Reduce Risk and Accelerate Innovation Around its Oracle Systems23.7.2025 15:00:00 CEST | Press release
Top ranked Australian university selects Rimini Support™, Rimini Protect™ and Rimini Connect™ for its Oracle systems to focus IT resources towards strategic initiatives that deliver exceptional student experiences Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced that the top-ranking higher learning institute in Australia, The University of Melbourne, has engaged Rimini Street to enable greater digital innovation investments for its organization consisting of 55,000 students and 10,000 staff. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250723436719/en/ The University of Melbourne Selects Rimini Street to Reduce Risk and Accelerate Innovation Around its Oracle Systems By selecting Rimini Support™, Rimini Connect™ and Rimini Protect™ for its Ora
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom